Skip to content
Axe Capital logo Axe Capital Trading News

Netflix Stock: Should You Buy the Post-Earnings Dip?

2026-10-26 16:52 •David Jagielski, Cpa •The Motley Fool Neutral Axe Cap view: Selective •Equities•Earnings •NFLX

Axe Cap view

Netflix’s Dip: Patient Buyers Could Profit

Netflix missed big growth expectations but trades at a more attractive valuation, tempting long-term buyers.

Netflix’s latest earnings showed steady revenue and earnings per share, but the guided slowdown in growth spooked the market. The stock has dropped 30% this year, making it cheaper relative to expected profits than many US tech peers. For South African investors, this matters mainly through the USD/ZAR exchange rate—Netflix revenues come in dollars, so a weaker rand raises the local cost but also signals broader dollar strength pressure on growth stocks. Locally, we see no direct JSE equivalent with similar streaming exposure, so rely on a USD/ZAR view. If the rand remains volatile or strengthens, that could blunt Netflix’s US-dollar based gains for local investors. Long-term, 17 times forward earnings is not expensive for a company still growing double digits, but patience will be key as short-term hurdles mount. Watch for how global inflation and consumer spending trends evolve, since those could derail recovery prospects. this is just our opinion and not financial advice

How I would invest

Watch Netflix closely for a possible entry on further dips, especially if USD/ZAR stabilizes below 18. Avoid aggressive buying now given guidance uncertainty and currency risk.

What I would watch
  • NFLX
  • USD/ZAR
What could go wrong
  • global consumer spending slows further
  • rand weakens sharply against the dollar
How strongly I feel

5/10

Netflix reported Q3 earnings that met revenue expectations and beat on EPS, but disappointed the market with underwhelming full-year guidance projecting 13% revenue growth. The stock has declined 30% year-to-date and is now trading at a forward P/E of 17, below the S&P 500 average of 19. Despite near-term headwinds around slowing growth, the analyst suggests the stock may be an attractive buy for patient investors given its reduced valuation and double-digit growth fundamentals.

Our take is based on reporting first published by The Motley Fool.

Read the original story